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In an earlier publication (1), it was pointed out that mice, to which anti-SK 
Columbia or anti-Semliki Forest virus sera, prepared in swine, had been given 
intraperitoneally,  were resistant  to infection with  the appropriate virus when 
challenged a few hours later. They were also resistant to the same viruses when 
rechaUenged 15 or 20 days later.  In contrast, mice that had been treated with 
helenine within a few minutes of receiving the antiviral sera, although resistant 
when exposed to the viruses a few hours later, frequently failed to withstand re- 
challenge with the same viruses 15 or 20 days later. This observation was inter- 
preted  at  the time as indicating  that helenine in some manner prevented the 
virus given in the initial infection from eliciting an effective immune response 
and hence left the mice that had been treated with both helenine and antiviral 
serum still susceptible to later rechallenge with virus. 
It has been subsequently found that the earlier interpretation of this phenom- 
enon was not correct and that, in fact, as will be shown, the initial infection with 
virus plays no role at all in it. The present paper will describe experiments indi- 
cating that helenine possesses the capacity to prevent the establishment of pas- 
sive viral immunity by antiviral serum and that the phenomenon is reproducible 
with antiserum prepared in heterologous hosts (swine, rabbits, and guinea pigs) 
but not with homologous (mouse) antiviral serum. 
Materials and Methods 
Virus,  Mice,  and  Hdenine.--The  source and  method  of administration  of the  Semliki 
Forest virus used in the present experiments as well as the source and strain of mice employed 
has been outlined in a recent paper (2). Also the method presently employed in the preparation 
of helenine was given in detail in the same paper. 
Anti-Sendiki Forest Virus Serum.--The anti-Semliki serum was prepared in either swine, 
rabbits,  guinea pigs, or mice. If of swine origin, it was drawn by jugular or tail bleeding 2 to 
3 wk after either a single intraperitoneal injection of virus, in infected mouse brain, or the same 
interval  after the second of two such injections spaced at an interval  of from 2 to 4 wk. Anti- 
serum of rabbit and guinea pig origin was drawn by jugular bleeding 2 wk after the second 
of two intraperitoneal  injections  of virus  in infected  mouse brain  at  8-day intervals.  The 
rabbit and guinea pig and most of the swine anti-Semliki sera employed in the present experi- 
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ments each represented a  pool of the serums of several animals. The anti-Semliki serum of 
mouse origin was obtained from pools of mice that had survived two or  more injections of 
virus in experiments in which immunity had been conferred by various procedures. The anes- 
thetized animals were bled by decapitation and the blood, after dotting, was either ground 
in a TenBroeck grinder with the addition of one part of saline,  containing 10 mg of strepto- 
mycin sulfate and 2000 units of penicillin G per ml, to each two parts of mouse blood, or serum 
was collected by centrifugation in the usual manner. So far as could be told, there was no 
difference in the results obtained whether ground whole mouse blood or mouse serum alone 
was employed. 
In the experiments to be outlined, the antiviral serum was, except as otherwise noted, 
injected intraperitoneally and helenine, where employed in conjunction with serum, was also 
administered intraperitoneally. Both  the antiserum and  the helenine were given in 0.5  ce 
amounts to each animal. In instances in which mixtures of antiserum and helenine were ad- 
ministered, the mixing was done just prior to inoculation and the total amount of the mixture 
injected was 1 cc. Inoculation with virus was routinely by the subcutaneous route under the 
loose skin of the back. 
RESULTS 
Prevention of the Establishment  of Passive  Immunity by lteterologous Antiviral 
Serum in Mice Treated vatk Helenine 
Groups of mice were injected intraperitoneally with anti-Semliki serum of 
swine origin 4, 8, 12, 16, and 21  days before inoculation subcutaneously with 
Semliki Forest virus. To a portion of themice in each group, the antiserum injec- 
tion was followed 2 hr later by an intraperitoneal injection of helenine. The re- 
sults gotten in several separate experiments have been combined and recorded 
in Table I. As shown in this table, most of the mice in the groups receiving anti- 
serum alone survived challenge with a dose of virus that killed all of 22 control 
mice, regardless of whether the antiserum preceded the virus by 4, 8, 12, 16, or 
21 days. Similarly, most of the mice that received antiserum and helenine 4 and 
8 days before virus inoculation also  survived. However, of the groups of mice 
that had been given antiserum and helenine 12, 16, and 21 days before virus 
inoculation, the findings were quite different. Here 8 of the 14 mice treated 12 
days before infection survived while only 1 each of the groups of 14 treated 16 
and 21 days before inoculation failed to succumb to the virus infection. 
The animals surviving initial infection with virus in all groups were then re- 
challenged 12 to 15 days later with the same dose of virus they had initially 
withstood. Again most of the mice that had received only anti-Semliki serum 
withstood rechallenge with the same dose of virus they had initially survived. 
However, of the mice that had survived infection 4, 8, and 12 days after receiv- 
ing antiserum and helenine, most succumbed on later rechallenge with virus. 
They thus behaved on rechMlenge similarly to those groups challenged initially 
16 and 21 days after antiserum and helenine. 
It is apparent from these findings that although anti-Semliki serum of swine 
origin can passively protect mice against infection with Semliki Forest virus for itCaARD  ~.. saorx  17 
at least as long as 21 days, helenine prevents the establishment of this passive 
immunity. The findings recorded in Table I  further indicate that, to demon- 
strate blocking  of the establishment of passive  protection, a  period  of time 
longer than 8 days must elapse between the administration of the antiserum and 
helenine and challenge with virus.  It is believed that excess antibody remains 
available~ unaffected by helenine, for at least this long, and that this available 
TABLE I 
Influeme  of the lntervd between Administration of Antiviral Serum and Infection with 
Virus on the Effeaiveness of Hdenin~ in Pr~enling the Establishment of 
Passive Immunity 
Injected intraperitoneslly  with 
Anti-Semiiki Forest virus serum (swine) 
Anti-Semliki Forest virus serum  (swine) 
followed in 2 hr by helenine 
Interval by which 
trestment preceded 
infection 
days 
4 
8 
12 
16 
21 
4 
8 
12 
16 
21 
Initial inoculation 
with Semllkl 
Forest virus 
Survivors 
19/20" 
7/7 
7/7 
6/6 
13/14 
26/27 
13/14 
8/14 
1/14 
1/14 
Controls, average days survived =- 4.2  0/22 
Challenge inocula- 
tion with Semllkl 
Forest virus 
Survivors 
15/19~ 
7/7 
5/7 
4/6 
13/13 
1/26 
2/13 
1/8 
1/1 
1/1 
Surviving mice  , 
No. of mice in group 
Surviving mice challenged 12 or 15 days after initial infection with same dose of virus. 
antibody persisting, perhaps in circulation, accounts for the result gotten in the 
groups of mice challenged with virus 4 and 8 days after antiserum and helenine. 
That persisting  passive protection did not establish even in these groups is in- 
dicated by their fully fatal susceptibility to infection with virus when rechal- 
lenged 12 or 15 days later. 
Persistent, of Passive Immunity in Mice Conferred by Swine Anti-S~nliki 
Serum.uThe findings oufllned in the preceding section and recorded in Table 
I indicated that anti-Semliki Forest virus serum of swine origin conferred solid 
passive protection in mice against the virus for at least 21 days whereas mice 
given the same serum and then treated with helenine had lost their passive pro- 
tection by 16 days. It seemed of interest in the light of these findings to deter- 18  ANTIVIRAL  SUBSTANCE  FROM  PENICILLIUM  FUNICULOSUM.  VI 
mine just how long passive protection to the virus might persist following the 
administration of swine antiviral serum. 
Four groups of 7 mice each were injected with swine anti-Semliki serum and 
then at intervals of roughly 3, 4, 5, and 8 wk were challenged with a dose of 
Semliki Forest virus sufficient to cause death of all the control animals. 
As shown by the results recorded in Table II, all of the mice challenged 18 
days after antiserum and most of those challenged at 27 and 39 days survived 
TABLE II 
The Period of Persistence  of Passive Prvtection to Semliki Forest Virus Conferred upon Mice by 
their Injection with Anti-Semilike  Serum of Swine Origin 
Injected intraperitoneally  with anti-Semlikl serum (swine) 
Result of inoculation with Semlike Forest virus 
Interval by which serum treatment 
preceded infection 
days 
18 
27 
39 
58 
Survivors 
7/7* 
6/7 
5/7 
O/7 
Controls, untreated  0/28 
Surviving mice 
No. of mice in group 
an ordinarily fatal dose of Semliki Forest virus. However by 58  days, the pas- 
sive protection conferred by the antiserum had completely waned and all 7 mice 
succumbed to the  challenge infection. The period of adequate persistence of 
passive protection conferred by swine anti-Semliki serum is therefore something 
more than approximately 5 wk but less than approximately 8 wk. 
In~uence of the Time of Administration of ttdenine on Its Ability to Prevent the 
Establishment of Passive Immunity by Antiviral Serum 
In an earlier paper dealing with the antiviral effect of helenine on mice in- 
fected with  Semliki  Forest virus,  it  was  shown  that  the  optimal  effect was 
achieved if the helenine was administered during a 36 hr period extending from 
12 to 48 hr before infection (2). With the view in mind that the optimal time 
of effectiveness of helenine in preventing the establishment of passive immunity 
by antiviral serum might correspond to that during which it was known to exert 
its optimal effect on virus infection, experiments were carried out in which hel- 
enine was given at various time intervals before and after the administration RICHARD v..  SHOP~.  19 
of antiviral serum. If the timing of maximal effectiveness of helenine in repro- 
ducing the two phenomena was similar, the possibility would be apparent that 
they might result from some common effect of helenine on the host. 
In the experiments to be described, groups of mice were given anti-Semliki 
TABLE  HI 
Influence  of Rdogive  Time  of Administration  of Antiserum  and Hdenine  on the Ability  of 
Hdenine  to Prevent the Establishment  of Passive Immunity 
by Heterologous Antiserum 
Injected intraperitoneally with 
Anti-Semliki serum (swine) 
Helenine  4  days before  .  ,,  .  ,s 
sc  3  st  ¢s  ss  tl  ts  t¢ 
ss  2  st  ts  ss  ts  s¢  ts 
st  1  st  tc  st  t¢  cs  ts 
,,  12  hr  "  "  "  "  " 
tt  8  tc  ss  ¢t  tt  ¢t  tc 
,,  4  ,s  ,t  .  .  ,,  . 
st  2  tc  ss  st  tt  tt  st 
"  mixed with  "  "  "  " 
s,  2  hr  after  "  "  "  " 
-  4  ,s  ,,  ,,  ,,  ,,  . 
t~  8  tt  ts  t~  tc  ts  ts 
"  12  ,,  .  st  .  .  . 
"  1  day  "  "  "  "  " 
"  2  ,t  ,,  ,,  .  ,  . 
~t  3  st  ts  st  tt  ts  ts 
-  4  -  -  -  -  -  - 
st  7  tt  st  st  ts  tt  is 
Controls, untreated 
Inoculation with Semliki 
Forest virus 3 wk after 
antiviral serum 
Survivors 
39/49* 
2/14 
3/14 
4/13 
6/35 
1/7 
1/7 
1/7 
6/26 
4/27 
6/40 
2/6 
6/20 
2/6 
8/26 
4/14 
10/14 
10/14 
18/20 
1/36 
•  Surviving mice 
No. of mice in group 
serum of swine origin intraperitoneally. Some of these received no further treat- 
ment while others were given helenine intraperitoneally at various intervals be- 
fore or after  the antiserum.  All,  together with untreated  control mice of the 
same age, were inoculated subcutaneously with Semllki Forest virus 3 wk after 
their serum treatments. The results given in Table III represent a composite of 
the findings in the experiments that have been carded out. 
As shown in Table III, 39 of 49 of the mice that received anti-Semliki serum 20  ANTIVIRAL  SUBSTANCE  ]~ROM PENICILLILT~  FUNICULOSU~.  VI 
alone 3 wk before infection survived a dose of virus that killed all except 1 of 
36 control mice. Helenine mixed with the antiviral serum at time of adminis- 
tration or injected from 2 hr to 4 days prior to antiserum interfered materially 
with the establishment of passive protection by antiviral serum. Helenine in- 
jected from 2 hr to as long as  2 days after antiviral serum administration also 
prevented or diminished the establishment of passive viral immunity. Helenine 
given 3, 4, and 7 days after antiviral serum was without obvious effect on the 
capacity of antiserum passively to protect mice. It thus appeared that the pe- 
riod of time during which helenine was effective in suppressing the establish- 
ment of passive protection by antiviral serum covered a span of 6 days extending 
from at least 4 days before to 2 days after the serum administration. While this 
6 day period embraced the 36 hr period during which, as had been shown by 
earlier work (2), helenine was optimally effective in exerting an antiviral action, 
it was apparent either that the mechanism by which the passive immunity sup- 
pression was brought about differed from that by which the antiviral action, 
was effected or that, ff the mechanisms involved were similar, there were quan- 
titative differences in the sensitivity in which they were expressed by the host. 
Since evidence has been adduced to indicate strongly that the  antiviral effect 
of helenine results from the induction of interferon by the  treated host (3), it 
is apparent that the passive immunity suppressing effect of helenine  either is 
not mediated by helenine-induced interferon or, if it is so mediated, the  sensi- 
tivity of the host differs materially in the expressions of the two  phenomena. 
Failure of ttelenine to Prevent the Establishment  of Passive Immunity in Mice 
by Homologous Antivirat Serum 
From the findings of the experiment outlined in Table I, it was apparent that 
the site of action of helenine in preventing the establishment of passive immu- 
nity following the administration of antiviral serum was not on antibody that 
persisted in circulation following its administration. Rather the lapse of a period 
in excess of 8 days for the acquisition of full effectiveness in blocking passive 
immunity suggested that either helenine acted to prevent the fixation of anti- 
body to some cellular site in the host where it was stored, or in some obscure 
manner, effected the early destruction of antibody. Since the antibody in the 
initial experiment was swine protein, the question arose as to whether this block- 
ing or destructive effect by helenine would be equally effective against homol- 
ogous antibody of mouse origin. In order to attempt to answer the question, an 
experiment was  conducted in which anti-Semliki serum of mouse  origin was 
substituted for the swine antiviral serum. 
In this experiment, 25 mice were given mouse anti-Semliki serum and another 
25 received the same serum followed 2 hr later by helenine. 21 days later these 
animals, together with 18 control mice of the same age, were challenged with 
Semiiki Forest virus. As  shown in Table IV, of the mice in the two treated 
groups, all in both groups except one that received antiserum alone survived, RICHARD E. SHOPE  21 
while the control  animals  died. Helenine had therefore  failed to prevent the 
establishment of passive  immunity from mouse  anti-Semliki serum,  a  result 
quite the opposite of what had been found when swine antiviral serum had been 
employed to establish  passive immunity. Furthermore,  almost all of the sur- 
viving mice also withstood rechallenge with  the same  dose  of virus 13 or 21 
days after initial infection. The observation of this difference in the effectiveness 
of helenine in preventing passive immunization with heterologous  (swine) but 
not homologous  (mouse)  antiviral serum suggested  the possibility  that  the 
blocking effect of helenine might be directed not against the antibody itself, but 
rather against foreign protein labeled as antibody. 
TABLE  IV 
Failure of tIdenine  to Prevent the Establishment of Passire Immunity to Semliki Forest Virus 
Conferred by Homologous (Mouse) Antlviral Serum 
Injected intraperitoneally  with 
Anti-Semliki  Forest  virus  serum  (mouse) 
alone 
Anti-Semliki  Forest  virus  serum  (mouse) 
followed in 2 hr by helenine 
i Initial inoculation  with 
Semliki Forest virus 21 
days after viral antiserum 
Survivors 
24/25~ 
25/25 
Controls, untreated  0/18 
Challenge inoculation* 
with SemlikiForest 
virus 
Survivors 
23/24 
22/25 
* Approximately half of the mice surviving in each group were challenged 13 days and the 
remainder 21 days after initial infection. 
Surviving mice 
No. of mice in group 
Persistence of Viral Antibody inSera of Mice Injected with Anti-Semliki Serum. 
--It has been suggested  earlier in this paper in connection  with the findings 
recorded in Table I that the persistence of antibody in the circulation for some- 
what over a week might account for the failure of helenine to interfere with 
passive protection when the challenge with virus was given soon after the ad- 
ministration of antiserum and helenine. The findings detailed in the preceding 
section and recorded in Table IV, indicating that helenlne failed completely to 
interfere with  the  establishment of passive  viral immunity by anti-Semliki 
serum of mouse  origin further raised  the question of whether perhaps there 
might be a difference in the time of persistence in the circulation of anti-Semliki 
serum of swine or mouse origin. To settle the point, mice were injected intra- 
peritoneally with either swine or mouse anti-Semliki  serum of approximately 
similar neutralizing titers. 3, 6, and 15 days later, blood was collected by de- 22  ANTIVIRAL  SUBSTANCE  ~'RO~W PENICILL~  FUNICIYLOSU~I.  VI 
capitation under anesthesia from groups of 7 animals  receiving each type of 
antiserum and the pooled sera from each group tested in mice for the presence 
of neutralizing antibody. 
The results recorded in Table V are not particularly clear-cut. However, on 
the basis of prolongation of survival time of the mice receiving mixtures con- 
talnlng some of the sera under test, compared with the survival time of the con- 
TABLE  V 
The Persistence of Mouse and Smine Anti-Semliki  Virus Antibody in the Sera of Injected Mice 
Source of anti-Semlikl 
serum administered 
to  mice 
Swine 
tc 
ct 
Mouse 
tt 
Interval between antlseru~ 
injection and test for 
antibody in sera of 
injected mice 
days 
15~ 
6 
3 
15 
6 
3 
Results of tests for presence of neutralizing antibody 
in sera of injected mice 
Test mice surviving* 
0161 
1/6 
i/6 
0/6 
2~ 
2~ 
Average days survived 
4.3 
5.,5 
7.1 
4.0 
7/7 
8.0 
Controls (saline)  016  3.3 
* 1  to  2  dilutions of mouse serum mixed with  -4-100 1W,_LD of Semi/ki  Forest  virus ad- 
ministered  intraperitoneally. 
~5 Tested as sera from pools of 7 mice. Comparable groups of 7 mice withstood challenge 
with =t=1000 MLD of Semliki Forest virus. 
Surviving mice 
§ No. of mice in group 
trol mice, there is evidence that the sera obtained from mice 3 and 6 days after 
they had received either swine or mouse anti-Semlild serum contained small 
amounts of protective antibody. The sera drawn from mice 15 days after they 
had received anti-Semliki serum contained little if any protective antibody. So 
far as can be tom from the findings, the mouse anti-Semliki serum persisted in 
the circulation of injected mice only slightly if at all longer than that from swine. 
Certainly any difference that exists is not sufficient to account for the differences 
observed in the effectiveness of helenine in suppressing the establishment of pas- 
sive viral protection by the two types of antiserum. 
The Effect of Helenine on the Passive Immunization of Mice to Semliki Forest 
Virus by Various Heterologous and Homologous Anti-Sendiki Sera 
In order further to explore the possibility that the interference of helenine 
with the establishment of passive viral immunity by antiserum of swine origin PaCHAR9 E. SHOI'E  23 
was a function of the heterologous nature of the antiserum, tests were carried 
out with anti-Semliki sera prepared in two other heterologous hosts. Rabbits 
and guinea pigs were immunized to Semliki Forest virus, as described earlier, 
to furnish two other antisera that, like that prepared in swine, would be heter- 
ologous to the mouse in which they were to be tested. A comparison of the effec- 
tiveness of helenine in modifying the establishment of passive immunity by 
three heterologous antiviral sera together with its failure to influence the estab- 
lishment of passive immunity by two samples of homologous (mouse) antiviral 
sera will be presented. 
Six groups of 28 or more mice each were injected intraperitoneally with anti- 
Semliki serum prepared  respectively in swine (two samples),  rabbits,  guinea 
pigs, and mice (two groups). 4 hr preceding the injection of antiserum, one half 
of each of the groups of mice received helenine intraperitoneally. The virus neu- 
tralizing titers of the six antiserum samples, as determined by intraperitoneal 
injection into mice of mixtures of a  fixed amount of virus with diminishing 
amounts of antiserum, indicated that not more than a 50-fold difference in neu- 
tralizing titer existed between any of the serum samples. Ranged in order from 
highest to lowest neutralizing potency, the six antiserum samples tested were 
guinea pig, rabbit, swine A, mouse pool A, swine B, and mouse pool B. 
18 days after the administration of antiserum, all of the treated mice together 
with 27 control animals were inoculated subcutaneously with Semliki Forest 
virus. The results of this experiment are outlined in Table VI. 
As shown in Table VI, all six of the antiserum samples given alone effectively 
protected mice against a  regularly fatal dose of Semliki Forest virus adminis- 
tered 18 days later and their species of origin seemingly did not influence their 
effectiveness. The results obtained on challenging the mice that had received 
the same six samples of antisera 4 hr after helenine were, however, quite differ- 
ent for among these groups only the antisera of mouse origin gave full protec- 
tion. The mice in groups that had received antisera of swine, rabbit or guinea 
pig origin, preceded by helenine, were largely not protected against the challenge 
virus, indicating that the helenine had in some way prevented the establishment 
of passive protection by these heterologous antiviral sera. That the virus neu- 
tralizing titers of these sera played no significant role in the results obtained is 
indicated by the fact that mouse pool B anti-Semliki serum had the lowest titer 
of any of the others in the experiment and the titer of the mouse pool A serum 
was below that of the guinea pig, rabbit, and swine A sera. 
These findings made it apparent that the capacity of helenine to prevent the 
establishment of passive protection to Semliki Forest virus in mice by various 
species types of anti-Semliki serum was in some way associated with the origin 
of the antiserum from hosts heterologous to mice in which the tests were con- 
ducted. The most likely explanation for the results obtained would seem to be 
that helenine, in some as yet unexplained manner,  enhances the mouse's ca- 
pacity to recognize the heterologous nature of these foreign host proteins and 24  ~VrIVI~L  SUBSTANCE  FROM  PENICILLIUM  FUNICULOSUM.  VI 
prevent their establishment. The failure of helenine to interfere with the estab- 
lishment  of  passive  immunity  conferred  by  viral  antibody  in  homologous 
(mouse)  serum  serves further  to indicate strongly its action is not on anti- 
body per se but rather on the gamma globulin comprising the antibody. The 
action appears to affect foreign protein and is detectable in the tests conducted 
merely because the heterologous protein is labeled as viral antibody. 
Since infected mouse brain had been employed in immunizing the mice, swine, 
TABLE VI 
The  Capacity  of  Helenine  to  Prevent  the  Establishment  of  Passive  Viral  Immunity  in  Mice  by 
Antg-Semliki  Sera  Produced  in  Several  Species  of Hosts 
Injected intraperltoneally with 
Mouse pool A anfi-Semliki serum 
¢c  cc  B  $c  ct  ~ 
Swine A  "  "  " 
Rabbit  "  "  " 
Guinea pig  "'  "  " 
Mouse pool A anfi-Semliki serum 4 hr after helenine 
Swine A  "  "'  "  "  "  "  " 
Rabbit  "  "  "  "  "  "  " 
Guinea pig  "  "  "  "  "  "  " 
Inoculation with Semllki 
Forest virus 18 days after 
antiviral serum 
Survivors 
14/14" 
14/14 
17/21 
21/21 
14/14 
13/13 
14/14 
14/14 
6/20 
6/21 
1/21 
1/lS 
Controls, untreated  0/27 
Surviving mice  , 
No. of mice in group 
rabbits, and guinea pigs supplying the antiviral sera in these experiments, and 
since challenge of the passively protected mice had been with infected mouse 
brain,  there seemed some remote possibility that anti-mouse antibodies con- 
ceivably induced in the sera of the heterologous hosts might, in some obscure 
manner, have influenced the outcome of these experiments. In order to rule out 
such a possibility, groups of mice were injected with representative heterologous 
and homologous antiviral sera, either alone or in conjunction with helenine. 18 
days later these animals were inoculated with Semliki Forest virus in infected 
guinea pig instead of infected mouse brain. The results parallded in their en- 
tirety those recorded in Table VI, indicating that the mousiness of neither the 
antivlral serum nor the challenge virus had influenced the experimental out- 
come. RICHARD E. SHOPE  25 
Attempted Exhaustion  of the Capacity of Hdenine to Interfere with the Estab- 
liskraent of Passive Viral Immunity.--In earlier work (2) it was shown that re- 
peated injections of helenine at 2- or 3-day intervals weakened or abolished its 
antivirus effect against Semllki Forest virus. Subsequent work (3) has indicated 
that the antivirus effect of helenine results from its induction of interferon in 
hosts to which it is administered. The finding that the antivirus effect could be 
exhausted by multiple injections of helenine was taken as evidence that the 
induced antivirus material was either present in limited supply in host cells or 
was capable of only limited elaboration there. 
In order to learn whether the capacity of helenine to interfere with the estab- 
TABLE  VII 
Attempted Exhaustion of Hdenine Effect by Multiple Repeated Injections before Administration 
of Swine Anti-Semliki Serum 
Helenine intraperitoneally at 2 to 3-day intervals  Inoculation with SemUki Forest virus 18 days 
prior to swine anti-Semllki  serum  after antiviral serum 
No. of injections  of helenine*  Survivors 
7  0/21, 
1  2/20 
0 (antiserum alone)  < 13/14 
Controls, untreated  0/7 
* Last or only injection of helenine preceded the single administration of serum by 4 hr. 
Surviving mice 
:~  No. of  mice in  group 
lishment of passive immunity by heterologous viruS antiserum was directly re- 
lated to its antiviruS activity, an experiment has been conducted to test the 
possibility. In this experiment, swine anti-Sem|ikl serum usonewas administered 
to one group of mice and to a second group, a single injection of helenine was 
administered 4 hr before the swine anti-Semlikl serum. In the case of a  third 
group of mice, 6 injections of helenine were given at 2- or 3-day intervuss before 
the final dose of helenine was injected 4  hr before the administration of the 
swine anti-Semliki serum. As shown by the results recorded in Table VII, 13 
out of the 14 mice that had received anti-Semliki serum alone survived a stiff 
challenge with virus 18 days later. However, only 2 out of 20 mice that received 
helenine 4 hr before the swine anti-Semlikl serum survived. Among the group 
of 21 animals that received 6 injections of helenine at 2- or 3-day intervals prior 
to the helenine injection 4 hr before swine anti-Semlikl serum, none survived the 
challenge with virus 18 days later. This result indicated that multiple preceding 
injections of belenine did not exhaust or abolish  its effectiveness in preventing 
the establishment of passive virus immunity by heterologous antivirus serum. 26  ANTIVIRAL  SUBSTANCE  FROM  PENICILLIUM  FU'NICULOSUM.  VI 
Since multiple preceding injections had effectively diminished the antiviral ef- 
fectiveness of helenine, presumably mediated  through its induction of inter- 
feron, it appeared superficially either that the antipassive immunity effect must 
have a different basic mechanism than the antiviral effect or that, if the phe- 
nomena had the same basis, there were marked quantitative differences in the 
hosts' response in the two reactions. 
A  Comparison of Hdenine and Statolon in the Prevention of the Establishment 
of Passive  Viral Immunity by Swine A nli-Semliki Serum--Since both helenine 
(3) and statolon (4) share the property of inducing the production of interferon 
in hosts to which they are administered, it seemed that a comparison of the two 
for their ability to prevent the establishment of passive viral immunity would 
TABLE  VIII 
Comparison of Effectiveness of Helenine and Slatolon in Preventing the Establishment of Passive 
Immunity to Semliki Forest Virus by Swine Anti-Semliki Serum 
Injected intraperitoneally with 
Inoculation with Semllki Forest virus 
20 days after antiviral serum 
Survivors 
Swine anti-Semliki serum  5/7* 
Swine anti-Semliki  serum 2 hr before  helenine  1/14 
Swine anti-Semliki serum 2 hr before 2.5 mg statolon  0/11 
Controls, untreated  0/15 
• .  Surviving  mice 
No. of mice in group 
prove instructive in determining whether this phenomenon might be one medi- 
ated by interferon. If statolon failed to interfere with the establishment of pas- 
sive immunity by antiviral serum, it would suggest strongly that  interferon 
played no role, while if it, like helenine, did suppress passive immunization, the 
finding would suggest the possible involvement of interferon. 
Three groups of mice were injected intraperitoneaUy with anti-Semtiki serum 
of swine origin. 2 hr later two of the groups of animals that had received anti- 
serum were injected intraperitoneally, one with helenine and  the other with 
statolon. These, together with an untreated control group, were held under ob- 
servation for 20 days. The animals that had  received antiserum  and statolon 
(2.5 mg per mouse) looked rough for several days and 3 of the 14 in the group 
died. 20 days after the administration of antiserum, all groups of animals were 
challenged subcutaneously with a stiff dose (approximately 1000 MLD) of Sem- 
liki Forest virus. The 11 mice surviving in the statolon group had by then re- 
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As shown by the findings recorded in Table viii, s out of the 7 mice that had 
been given antiviral serum survived a challenge  infection that killed all of 15 
control mice. In contrast, of the 14 mice that had received the antivirM  serum 
followed by helenine,  only one withstood the virus challenge,  while of the 11 
mice remaining  in the group that had been given the antiviral serum followed 
by statolon, none survived challenge. These results indicated that statolon, like 
helenine, was capable of preventing the establishment of passive viral immunity 
by antiviral  serum of swine  origin.  These two antiviral  materials of reputed 
differing chemical composition (5, 6), but both known to be capable of inducing 
the production of interferon, thus shared yet another activity, that of interfering 
with the establishment in the mouse of passive viral immunity by antiviral sera 
heterologous to that host.  The possibility that interferon mediates both the 
antiviral and the antiforelgn immune protein activities of helenine and statolon 
appears as one requiring  more definitive study and one that will be considered 
more in detail in a subsequent publication. 
DISCUSSION 
All of the evidence obtained in this study indicates that the action of helenine 
in preventing the establishment of passive viral immunity by antiviral  serums 
of various foreign host sources results not from its effect upon antiviral antibody 
itself but rather from its effect upon the foreign host gamma globulin comprising 
the antibody. That the action is not directly on viral antibody is indicated by 
the complete inability of helenine  to interfere with the establishment of passive 
viral immunity in mice by antibody of mouse origin.  Viral  antibody prepared 
in swine,  rabbits, or guinea pigs,  on the other hand, is completely prevented 
from establishing passive immunity in mice if helenine  is administered to the 
mice during a period extending from 4 days before to 2 days after the antiserum. 
During this period of approximately 6 days, helenlne in some as yet unexplained 
manner prevents mice from acquiring passive viral immunity following the ad- 
ministration of the heterologous antiviral sera.  So far as can be told, the het- 
erologous and the homologous antiviral sera are of comparable efficacy in pas- 
sively protecting mice against infection with Semllki Forest virus if treatment 
with helenine  is withheld.  The most probable interpretation  of the findings 
under discussion,  therefore, would seem to be that helenine  exerts its effect on 
the establishment of passive viral immunity by virtue of some action that it has 
on the foreign gamma globulin comprising the viral antibody. The prevention of 
the establishment of passive viral immunity in mice by heterologous viral anti- 
body is an effect made experimentally apparent only by virtue of the fact that 
the heterologous gamma globulin, the material against which the helenine effect 
is expressed, happens to be labeled as viral antibody. 
The failure of helenine  to exert any effect on the establishment of passive 
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in preventing passive viral immunity by heterologous antiserum in the experi- 
ments under discussion permit of yet another rather self-evident conclusion. 
This is that helenine does not exert its effect directly but rather through induc- 
ing the host itself to elaborate the principle capable of selectively acting on the 
gamma globulin comprising the viral antibody. Were the action of helenine a 
direct one against immune viral gamma globulin, one would anticipate that it 
should be equally effective against either homologous or heterologous immune 
protein. Since it is not, but seemingly selects heterologous gamma globulin for 
its effect, the most apparent explanation would seem to be  that the activity 
resides in some material, probably naturally present in small quantity in the 
host under normal conditions, that is induced in excess quantity when the host 
is treated  with helenine. This induced material, whatever its nature may be, 
seemingly enhances  the  capacity  of  the  host  to  recognize  and  dispose  of 
foreign protein. As a result, the helenine-treated host handles foreign gamma 
globulin in such a maner as  to  prevent its establishment. Since the gamma 
globulin in  the  present  instance is  Semliki Forest  virus antibody,  animals 
treated with helenine do not establish passive immunity to that virus. This in- 
duced material, being of host origin, evidently does not recognize homologous 
gamma globulin and hence helenine does  not  prevent  the  establishment of 
passive  immunity originating from the  administration of homologous  anti- 
body. 
As was pointed out in an earlier paper (3) dealing with the mechanism of the 
antiviral action of helenine, one of the mechanisms, and the most likely one, by 
which helenine effects its antiviral activity is through the induction of inter- 
feron in the helenine-treated host. In the experiments being presently discussed, 
helenine induces interferon just as it did in the earlier antiviral experiments. 
However whether this induced interferon accounts for the action that helenine 
exerts in disposing of immune gamma globulin, as it is known to do in preventing 
viral infection, cannot be decided from the data so far at hand. 
In the work under discussion, several types of experiments have been carried 
out in an effort to learn whether the prevention of the establishment of pas- 
sive immunity from heterologous antiviral serum by helenine could, like its 
antiviral effect (2, 3), result from the induction of interferon in the host. Un- 
fortunately the experimental work so far carried out and presented in this paper 
does not permit of a clear-cut decision as to whether interferon induced by hel- 
enine accounts for its capacity to prevent the establishment of passive immu- 
nity by heterologous antiviral serums although they do not categorically rule 
out the possibility. 
The first experiment designed to test for a  parallelism between the antiviral 
(AV)  and the antipassive immunity (API) effects of helenine was the one re- 
corded in Table III. It had been shown in an earlier publication (2) that helenine 
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hr and extending to 48 hr before virus infection. Since evidence has been pre- 
sented to indicate that this AV effect resulted from interferon-induction in the 
treated host (3), it is apparent that, were the API effect of hdenine also medi- 
ated through induced interferon,  its period  of optimal effectiveness might be 
expected  to parallel  timewise the period of optimal AV  activity. The results 
gotten in the experiments under present discussion obviously were not parallel 
with the earlier AV findings in that hdenine exerted an optimal API effect for 
at least 4 days before to 2 days after antiserum administration. While this 6 
day period of optimal API effectiveness included the 36 hr period during which, 
as shown by earlier work (2), helenine exercised its optimal AV action, it ex- 
tended well beyond the AV period in both directions.  From the experiments 
under discussion, the suggestion is apparent that, although helenine probably 
exerts its AV effect through interferon induction in the treated host, evidence 
that induced interferon is responsible for the API effect of helenine seems less 
likely. However, the findings do not decisively rule out the possibility  and the 
lack of parallelism between the time of optimal effectiveness of hdenine in con- 
sumating the two effects may reflect merely a  quantitative difference in the 
sensitivity of the host to induced interferon in expressing the AV and the API 
effects. 
The second experiment designed to test for a parallelism between the AV and 
API effects of helenine was the one recorded in Table VII. It had been previ- 
ousiy shown, as reported in an earlier paper (2) that the AV effect of helenine 
could be diminished or exhausted if multiple injections at 2- or 3-day intervals 
preceded the final AV injection of hdenine. Based on the premise that the AV 
effect of helenine resulted from the induction of interferon in the injected host, 
the finding was interpreted as indicating that the capacity of a host to elaborate 
interferon under prolonged hdenine stimulation was finite and exhanstible, and 
that the eventual failure of helenine to exert its expected AV effect furnished 
tangible evidence for this eventual abolition  of interferon elaboration.  In the 
experiments  carried  out in the present work,  multiple injections  of helenine 
were given to mice preceding the final injection to elicit the API effect. It had 
been anticipated, if the mechanism by which helenine brought about the API 
effect and that by which it caused the AV effect were gmilar, that the API effect 
should be abolished just as had been the AV effect. However, such did not prove 
to be the case and the findings indicated that even six injections of helenine at 
2- or 3-day intervals prior to a final injection 4 hr before antiserum administra- 
tion did not abolish  or even apparently diminish the API effect of helenine. 
Since multiple preceding injections of helenine had effectively exhausted its AV 
effect, presumably mediated through the induction of interferon, it appeared 
superficially at least either that the API effect of hdenine had a different basic 
mechanism than the AV effect or that, if the phenomena had the same basis, 
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reactions.  A point of difference in the two reactions which probably should be 
taken into account concerns the fact that the optimal period of effectiveness of 
helenine in the AV effect extends over a period of only 36 hr whereas the API 
effect embraces a period of 6 days during which helenine is optimally effective 
in bringing it about. This difference in the period of optimal activity of helenine 
in expressing its AV and API effects, coupled with a possible difference in the 
sensitivity of the host's response to the substance,  induced by helenine, might 
account for a detectable lack of parallelism in the experiments under discussion. 
The third experiment designed to test for a parallelism between the AV and 
API effects of helenine was the one recorded in Table VIII. In this, helenine 
and statolon, both substances known to induce the elaboration  of interferon in 
hosts to which administered (3, 4),  and both capable  of exerting pronounced 
AV effects, were found also both to exercise a maximal API effect when tested 
under similar conditions. Thus the parallelism  as regards interferon induction 
and the manifestation of both an AV and an API effect was perfect so far as a 
comparative study of helenine and statolon could determine. The result of this 
third experiment  suggested  that there should be further serious study of the 
possibility  that the API effect like the AV effect of helenine was mediated by 
induced interferon. Experiments of a more definitive character dealing with the 
possible role of interferon in the API effect of helenine are in progress and will 
be reported later. 
SUMMAR~ 
1. Helenine prevents the establishment in mice of passive viral immunity by 
anti-Semlikl serum of swine, rabbit, or guinea pig origin. 
2. A period of 12 days must elapse, between the antiviral serum administra- 
tion and challenge with virus, for prevention of the establishment of passive 
immunity to become apparent. This period is believed to correspond to that in 
which injected antibody persists in circulation in the injected host. 
3. Helenine is effective in preventing the establishment of passive viral im- 
munity by heterologous antiviral sera when it is administered any time during 
a period of 6 days, extending from 4 days before to 2 days after injection of the 
antiviral serum. 
4. Helenine does not prevent the establishment of passive viral immunity by 
antiviral sera of mouse origin (homologous). 
5. Evidence is presented to indicate that the phenomenon of the prevention 
of the establishment of passive viral immunity by heterologous antiviral sera 
is not effected directly, but rather is mediated through some substance  that 
helenine induces the injected host to elaborate. 
6. The capacity to prevent the establishment of passive viral immunity could 
not be exhausted by repeated preceding injections  of helenine at 2- or 3-day 
intervals. ~UCHA~) E. SHOI~E  31 
7. Evidence is presented to indicate that the helenine-induced material does 
not act upon antiviral antibody per se but rather on heterologous foreign pro- 
tein that happens to be labeled as Semliki Forest virus antibody. This helenine- 
induced material, whatever its nature, appears to enhance the capacity of the 
injected host to recognize and dispose of foreign protein. 
8. Statolon, a material that like helenine is a known inducer of interferon, is, 
like helenine, also capable of preventing the establishment of passive viral im- 
munity by heterologous antiviral sera. 
9. Experiments designed to determine whether the induced material respon- 
sible for the antipassive immunity effect of helenine is interferon have yielded 
inconclusive answers thus far. 
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